Cardiac toxicity of targeted therapies used in the treatment for solid tumours: a review (Q38005052)

26 August 2017

title

Cardiac toxicity of targeted therapies used in the treatment for solid tumours: a review (English)

1 reference

26 August 2017

Marek Svoboda

1

1 reference

26 August 2017

Alexandr Poprach

2

1 reference

26 August 2017

Svatopluk Dobes

3

1 reference

26 August 2017

Igor Kiss

4

1 reference

26 August 2017

Rostislav Vyzula

5

1 reference

26 August 2017

publication date

1 September 2012

1 reference

Cardiovascular Toxicology

26 August 2017

published in

1 reference

26 August 2017

volume

12

1 reference

26 August 2017

issue

3

1 reference

26 August 2017

page(s)

191-207

1 reference

AMP-activated protein kinase: a cellular energy sensor with a key role in metabolic disorders and in cancer.

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007/S12012-012-9164-0

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12012-012-9164-0

Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12012-012-9164-0

Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12012-012-9164-0

Neuregulin activates erbB2-dependent src/FAK signaling and cytoskeletal remodeling in isolated adult rat cardiac myocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12012-012-9164-0

Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12012-012-9164-0

Clinical cardiac tolerability of trastuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12012-012-9164-0

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12012-012-9164-0

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12012-012-9164-0

Cardiac toxicity in breast cancer survivors: review of potential cardiac problems.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12012-012-9164-0

Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12012-012-9164-0

Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12012-012-9164-0

Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12012-012-9164-0

Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12012-012-9164-0

Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12012-012-9164-0

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12012-012-9164-0

Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12012-012-9164-0

The lack of target specificity of small molecule anticancer kinase inhibitors is correlated with their ability to damage myocytes in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12012-012-9164-0

An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12012-012-9164-0

Congestive heart failure is a rare event in patients receiving imatinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12012-012-9164-0

Dasatinib: An Anti-Tumour Agent via Src Inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12012-012-9164-0

Molecular basis for sunitinib efficacy and future clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12012-012-9164-0

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12012-012-9164-0

Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12012-012-9164-0

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12012-012-9164-0

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12012-012-9164-0

Cardiotoxicity induced by tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12012-012-9164-0

Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12012-012-9164-0

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12012-012-9164-0

Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12012-012-9164-0

Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12012-012-9164-0

Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12012-012-9164-0

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12012-012-9164-0

Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12012-012-9164-0

Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12012-012-9164-0

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12012-012-9164-0

Lapatinib-associated toxicity and practical management recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12012-012-9164-0

Beta-arrestin-mediated beta1-adrenergic receptor transactivation of the EGFR confers cardioprotection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12012-012-9164-0

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12012-012-9164-0

The TOR pathway: a target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12012-012-9164-0

Efficacy and Safety of Sirolimus and Everolimus in Heart Transplant Patients: A Retrospective Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12012-012-9164-0

Sunitinib, Hypertension, and Heart Failure: A Model for Kinase Inhibitor-Mediated Cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12012-012-9164-0

Cardiomyocyte PDGFR-beta signaling is an essential component of the mouse cardiac response to load-induced stress.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12012-012-9164-0

Alternative signaling: cardiomyocyte beta1-adrenergic receptors signal through EGFRs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12012-012-9164-0

Tackling heart failure in the twenty-first century

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12012-012-9164-0

Costameres, focal adhesions, and cardiomyocyte mechanotransduction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12012-012-9164-0

Cardiac hypertrophy: a risk factor for QT-prolongation and cardiac sudden death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12012-012-9164-0

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12012-012-9164-0

Role of biomarkers in chemotherapy-induced cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12012-012-9164-0

p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12012-012-9164-0

BRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12012-012-9164-0

10.1007/S12012-012-9164-0

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

26 August 2017

1041997117

0 references

1 reference